{"id":244423,"date":"2012-07-31T22:18:13","date_gmt":"2012-07-31T22:18:13","guid":{"rendered":"http:\/\/www.eugenesis.com\/schiff-nutrition-international-inc-announces-fiscal-2012-fourth-quarter-and-year-end-results\/"},"modified":"2012-07-31T22:18:13","modified_gmt":"2012-07-31T22:18:13","slug":"schiff-nutrition-international-inc-announces-fiscal-2012-fourth-quarter-and-year-end-results","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nutrition\/schiff-nutrition-international-inc-announces-fiscal-2012-fourth-quarter-and-year-end-results.php","title":{"rendered":"Schiff Nutrition International, Inc. Announces Fiscal 2012 Fourth Quarter and Year-End Results"},"content":{"rendered":"<p><p>    SALT LAKE CITY--(BUSINESS WIRE)--  <\/p>\n<p>    Schiff Nutrition International, Inc., (SHF),    announced results for the three- and twelve-month periods ended    May 31, 2012.  <\/p>\n<p>    We are pleased with our fourth quarter performance as it    reflects strong execution against our growth strategy, stated    Tarang Amin, president and chief executive officer. Net sales    grew 30%, driven by a 59% increase in our branded business. Our    gross profit margin grew 1,100 basis points to 49.5%,    reflecting our progress building premium brands, leading    innovation, expanding the channel and geographic footprint of    the company, pursuing acquisitions, and driving world-class    operations. Our probiotics and Airborne    acquisitions added to the strong contribution of our core    brands MegaRed and Move Free.\"  <\/p>\n<p>    Fiscal 2012 Fourth Quarter Results  <\/p>\n<p>    For the fiscal 2012 fourth quarter ended May 31, 2012, net    sales were $67.4 million, compared to $51.9 million for the    same period in fiscal 2011. The 30% increase reflects growth in    key brands, new product introductions and contribution from    acquisitions. Branded sales of $59.9 million were partially    offset by an expected decline in the private label business.    The higher mix of branded sales resulted in gross profit margin    of 49.5%, compared to 38.2% a year ago. Total operating    expenses increased to $27.1 million from $14.9 million a year    ago reflecting the anticipated increase in selling and    marketing expenses and $3.4 million in acquisition related    costs, $2.0 million of which was non-deductible for income tax    purposes. Net income for the fiscal 2012 fourth quarter was    $2.0 million, compared to net income of $3.1 million for the    same period in fiscal 2011. Earnings per diluted share were    $0.07 for the fiscal 2012 fourth quarter, compared to $0.10 for    the same period in fiscal 2011. Adjusted EBITDA, which is    defined as income from operations before depreciation,    amortization, stock-based compensation and completed    acquisition related costs, was $12.4 million for the fiscal    2012 fourth quarter, compared to $7.5 million for the same    period in fiscal 2011.  <\/p>\n<p>    Fiscal 2012 Full Year Results  <\/p>\n<p>    For the fiscal year 2012, net sales were $258.9 million,    compared to $213.6 million for fiscal 2011. Selling and    marketing expenses were $60.3 million, or 23% of revenue,    compared to $34.7 million, or 16% of revenue. Gross margin for    the fiscal year 2012 was 46.1%, compared to 38.0% for fiscal    2011. Net income for the fiscal year 2012 was $13.7 million,    compared to net income of $12.6 million for fiscal 2011.    Earnings per diluted share were $0.47 for the fiscal year 2012,    compared to $0.43 for fiscal 2011. Adjusted EBITDA was $38.7    million for the fiscal year 2012, compared to $28.9 million for    fiscal 2011.  <\/p>\n<p>    We are positioning Schiff as a leader in the nutritional    supplements category. Our fiscal year 2012 investments in brand    building and innovation drove strong sales and gross margin    growth. For fiscal 2013, we are committed to building upon this    momentum, concluded Amin.  <\/p>\n<p>    Company Outlook  <\/p>\n<p>    Fiscal 2013 net sales are expected to grow 40.0% to 43.0% as    compared to fiscal year 2012 net sales of $258.9 million.    Expected sales growth includes contributions from new products,    brand building and Airborne, which was acquired on March    30th. As previously announced, Airborne had net    sales of approximately $72 million for the twelve months ended    February 29, 2012. Gross profit percentage is expected to be in    the range of 48.0% to 50.0%. Selling and marketing expenses, as    a percentage of net sales, are estimated to be in the range of    25.0% to 27.0%. Other operating expenses are estimated at    approximately $35.0 million to $37.0 million. The company    anticipates its operating margin will be in the range of 12.5%    to 14.0%.  <\/p>\n<\/p>\n<p>See more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/schiff-nutrition-international-inc-announces-110500637.html;_ylt=A2KJjb2hWRhQlAwAkwP_wgt.\" title=\"Schiff Nutrition International, Inc. Announces Fiscal 2012 Fourth Quarter and Year-End Results\">Schiff Nutrition International, Inc. Announces Fiscal 2012 Fourth Quarter and Year-End Results<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SALT LAKE CITY--(BUSINESS WIRE)-- Schiff Nutrition International, Inc., (SHF), announced results for the three- and twelve-month periods ended May 31, 2012. We are pleased with our fourth quarter performance as it reflects strong execution against our growth strategy, stated Tarang Amin, president and chief executive officer. Net sales grew 30%, driven by a 59% increase in our branded business.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nutrition\/schiff-nutrition-international-inc-announces-fiscal-2012-fourth-quarter-and-year-end-results.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577479],"tags":[],"class_list":["post-244423","post","type-post","status-publish","format-standard","hentry","category-nutrition"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/244423"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=244423"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/244423\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=244423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=244423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=244423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}